Accumulating evidence indicates that the ␤-arrestins act as scaffold molecules that couple G-protein-coupled receptors to mitogen-activated protein (MAP) kinase signaling pathways. Recently, we identified the c-Jun N-terminal kinase 3 (JNK3) as a ␤-arrestin2-interacting protein in yeasttwo hybrid and co-immunoprecipitation studies. ␤-Arrestin2 acts as a scaffold to enhance signaling to JNK3 stimulated by overexpression of the MAP3 kinase ASK1 or by agonist activation of the angiotensin 1A receptor. Whereas ␤-arrestin2 is a very strong activator of JNK3 signaling, ␤-arrestin1 is very weak in this regard. The data also indicate that the specific step enhanced by ␤-arrestin2 involves phosphorylation of JNK3 by the MAP2 kinase MKK4. We reasoned that defining the region (or domain) in ␤-arrestin2 responsible for high level JNK3 activation would provide insight into the mechanism by which ␤-arrestin2 enhances the activity of this signaling pathway. Using chimeric ␤-arrestins, we have determined that sequences in the carboxyl-terminal region of ␤-arrestin2 are important for the enhancement of JNK3 phosphorylation. More detailed analysis of the carboxyl-terminal domains of the ␤-arrestins indicated that ␤-arrestin2, but not ␤-arrestin1, contains a sequence (RRSLHL) highly homologous to the conserved docking motif present in many MAP kinasebinding proteins. Replacement of the ␤-arrestin2 RRS residues with the corresponding KP residues present in ␤-arrestin1 dramatically reduced both JNK3 interaction and enhancement of JNK3 phosphorylation. Conversely, replacement of the KP residues in ␤-arrestin1 with RRS significantly increased both JNK3 binding and enhancement of JNK3 phosphorylation. These results delineate a mechanism by which ␤-arrestin2 functions as a scaffold protein in the JNK3 signaling pathway and implicate the conserved docking site in ␤-arrestin2 as an important factor in binding JNK3 and stimulating the phosphorylation of JNK3 by MKK4.
1
modulates the activity of a wide variety of signaling molecules including adenylyl cyclases, phospholipases, ion channels, and mitogen-activated protein (MAP) kinases (1) (2) (3) (4) (5) . Phosphorylation of activated receptors by GPCR kinases (GRKs) facilitates binding of arrestin proteins that serve to physically uncouple activated receptors from bound G-proteins (6 -9) . This process termed "desensitization" effectively terminates many of the classical G-protein signaling pathways. However, recent studies indicate that the arrestins also function as adapter molecules important not only in signal termination but also in the activation of additional signaling pathways emanating from GPCRs (10) .
Initial evidence implicating the ␤-arrestins as adapter molecules indicated that the ␤-arrestins directly interact with the heavy chain of clathrin, the clathrin adapter protein (AP-2), and the N-ethylmaleimide sensitive fusion protein (NSF) to promote endocytosis of activated GPCRs (11) (12) (13) . The ␤-arrestins also interact with the tyrosine kinase c-Src, and agonist stimulation of GPCRs redirects the cytoplasmic ␤-arrestin and c-Src molecules to the receptor (14) . Recruitment of c-SRC to activated GPCRs has been shown to mediate aspects of MAP kinase activation, receptor internalization, and granule release (14 -17) .
Whereas interaction of ␤-arrestins with c-Src is involved in the early steps leading to activation of MAP kinase pathways, the ␤-arrestins also function as scaffold proteins to mediate assembly of multiprotein MAP kinase cascades such as those for ERK and JNK (4, 18 -20) . The ␤-arrestins form complexes with Raf (MAP3K), MEK (MAP2K), and ERK (MAPK) to facilitate the activity of the MAP kinases ERK1 and ERK2 (17) (18) (19) . Agonist stimulation of angiotensin 1A receptor (AT1aR) or protease-activated receptor 2 (PAR2) results in the recruitment of ␤-arrestin and activated ERK to the receptor (18, 19) . It is unclear if the activated ERK then translocates to the nucleus to activate transcription or if it remains associated with internalized receptors and phosphorylates unknown cytoplasmic targets.
␤-Arrestin2 also functions as a scaffold to enhance signal transmission to the MAP kinase JNK3 (20, 21) . ␤-Arrestin2 interacts with ASK1 (MAP3K), MKK4 (MAP2K), and JNK3 (MAPK) to markedly enhance JNK3 phosphorylation. Overexpression of ASK1 or stimulation of the AT1aR leads to a marked increase in JNK3 phosphorylation that requires ␤-ar-restin2 (20) . Confocal microscopy experiments indicate that a complex containing ␤-arrestin2 and JNK3 is sequestered in the cytoplasm and associates with the activated AT1aR following agonist stimulation. Similar to the situation with ERK, it remains undetermined if activated JNK3 at some point translocates to the nucleus or if it remains associated with ␤-arrestin2 and internalized receptors where it phosphorylates unknown cytoplasmic targets. These results indicate that formation of multiprotein complexes mediated by the ␤-arrestins stimulates signal transmission resulting in phosphorylation of MAPKs such as the ERKs and JNKs.
It appears that ␤-arrestin2 functions as a scaffold protein analogous to the mammalian JNK-interacting proteins (JIPs) and the yeast protein Ste5 (22) (23) (24) . The scaffold proteins share a common feature in that they all enhance signal transmission resulting in activation of MAP kinases. These scaffold proteins share little or no sequence homology, although they appear to serve very similar roles in the stimulation of MAP kinase cascades (25, 26) . It is clear that scaffold proteins, such as ␤-arrestin2, interact with multiple members of the MAP kinase cascades; however, very little is known about the specific molecular details by which these proteins enhance signaling. More specifically, it is not known if these scaffold proteins facilitate signal transmission at multiple steps in the pathway (as may be the case with Ste5) or if one particular step in the pathway is specifically enhanced.
It is intriguing that although the ␤-arrestins share very high sequence homology (ϳ80%), they differ greatly with respect to their ability to enhance JNK3 phosphorylation (20, 27) . ␤-Arrestin1 is a weak stimulator of ASK1-driven JNK3 phosphorylation in comparison with ␤-arrestin2 (20) . Thus, the high degree of sequence similarity between ␤-arrestin1 and ␤-arrestin2 offers a unique opportunity to provide insights into the specific structural features of ␤-arrestin2 that permit it to act as a scaffold in the JNK3 pathway. Moreover, it is interesting that two molecules with very similar abilities to promote desensitization and receptor internalization, would have such markedly different abilities to act as scaffolds in the JNK3 signaling pathway.
In the present study, we have analyzed the mechanism by which ␤-arrestin2 enhances JNK3 stimulation driven by upstream kinases in the JNK3 pathway such as ASK1 and MKK4. We provide evidence that sequences in the carboxylterminal domain of ␤-arrestin2 direct the assembly of a complex that facilitates the phosphorylation of JNK3 by MKK4.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection-COS-7 African Green Monkey cells were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco's modified essential medium supplemented with 10% fetal bovine serum and penn/strep (Life Technologies, Inc.). Cells were routinely subcultured 1:10 three times weekly. COS-7 cells were transfected in 100-mm dishes with 5 g of total plasmid DNA and 20 l of LipofectAMINE according to the manufacturer's instructions. Cells were routinely harvested 48 h post-transfection.
Plasmids-Expression vectors for ␤-arrestin1(FLAG), ␤-arrestin2 (FLAG), arrestin1(FLAG), JNK3(HA), MKK4(HA), and ␤2-adrenergic receptor(FLAG) have been described previously (15, 20) . Expression vectors for FLAG-tagged ␤-arrestin chimeras were cloned into the pcDNA3 eukaryotic expression vector (Invitrogen). Briefly, for the ␤-arrestin1/2 chimera, DNA encoding a minimal KOZAK sequence and amino acids 1-184 of ␤-arrestin1 and DNA encoding amino acids 186 -410 of ␤-arrestin2 with a carboxyl-terminal FLAG tag were PCR amplified and cloned by three way ligation into the EcoRV sites of pcDNA3. For the ␤-arrestin2/1 chimera, DNA encoding a minimal KOZAK sequence and amino acids 1-185 of ␤-arrestin2 and DNA encoding amino acids 185-418 of ␤-arrestin1 with a carboxyl-terminal FLAG tag were PCR amplified and cloned by three way ligation into the EcoRV sites of pcDNA3. Expression vectors for the ␤-arrestin1(RRS) and ␤-arrestin2(KP) mutants were constructed in a similar manner. For the ␤-arrestin1(RRS) mutant, DNA encoding a minimal KOZAK sequence and amino acids 1-184 of ␤-arrestin1 and DNA encoding amino acids 185-418 of ␤-arrestin1 (containing RRS in place of KP at residues 195-196) with a carboxyl-terminal FLAG tag were PCR amplified and cloned by three way ligation into the EcoRV sites of pcDNA3. For the ␤-arrestin2 (KP) mutant, DNA encoding a minimal KOZAK sequence and amino acids 1-185 of ␤-arrestin2 and DNA encoding amino acids 186 -410 of ␤-arrestin2 (containing KP in place of RRS at residues 196 -198) with a carboxyl-terminal FLAG tag were PCR amplified and cloned by three way ligation into the EcoRV sites of pcDNA3. All sequences were confirmed using an automated ABI DNA sequencer (Howard Hughes Nucleic Acid Facility, Duke University).
Immunoprecipitations-Whole cell extracts were prepared 48 h posttransfection by lysing cells in 1 ml of lysis buffer (LB) (20 mM HEPES, 0.5% Nonidet P-40, 250 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 2.5 g/ml aprotinin, 25 g/ml leupeptin, 100 M sodium orthovanadate, and 50 mM sodium fluoride) for 20 min at 4°C. The supernatant was clarified by centrifugation and was stored at Ϫ80°C until use. Approximately 25 g of clarified supernatant was diluted in 2ϫ sample buffer and saved as whole cell extract. HA-tagged proteins were immunopurified from the remaining supernatant with 20 l of anti-HA (HA.11) affinity matrix (Covance) for Ͼ3 h with constant rocking at 4°C. Immunocomplexes were washed 3-4 times in lysis buffer and diluted in 50 l of 2ϫ sample buffer. Immunocomplexes (20 l) were resolved by SDS-PAGE, transferred to nitrocellulose, and analyzed by immunoblot as described below. Bound HA and associated proteins were detected by immunoblot as described below.
Immunoblot Analysis-Whole cell extracts or immunocomplexes were boiled for 10 min, separated on 4 -20% gradient SDS-polyacrylamide gels (Novex), and transferred to supported nitrocellulose filters (Schleicher and Schuell) using a Millipore semi-dry electrophoretic transfer apparatus. Filters were stained with Ponceau S stain to visualize equal loading of protein in all lanes. Nonspecific reactivity was blocked by incubation in Tris-buffered saline containing 0.1% Tween 20 (TBST) and 5% nonfat dried milk (BLOTTO). Rabbit antiserum directed against FLAG, HA, and JNK3 (Santa Cruz Biotechnology, Inc.) were used at a 1:1000 dilution according to the manufacturer's specifications. Rabbit antiserum directed against phospho-JNK (Promega) or phospho-MKK4 (New England Biolabs) were used at a 1:2000 dilution according to the manufacturer's specifications. Mouse monoclonal antibody directed against MKK4 (Transduction Laboratories) was used at a 1:2000 dilution according to the manufacturer's specifications. Appropriate secondary anti-mouse or anti-rabbit antibodies (Amersham Pharmacia Biotech) were used at a dilution of 1:2000 in BLOTTO to detect bound primary antibody. Reactive proteins were detected by incubation of washed filters (TBST) in the enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech) followed by exposure to autoradiographic film. Immunoblots were also quantified using a Fluor-S TM MultiImager and Quantity One software (Bio-Rad Laboratories, Hercules, CA).
␤2-Adrenergic Receptor Internalization-Agonist-induced receptor internalization was assayed essentially as described (28) . Briefly, 48 h following transfection, cells containing FLAG-tagged ␤2-adrenergic receptors were subjected to stimulation with 10 M isoproterenol (iso) for 30 min at 37°C. Stimulated cells were then incubated for 1 h with anti-FLAG primary antibody on ice, incubated for 1 h with fluorescein isothiocyanate-conjugated anti-mouse antibody on ice and fixed in phosphate-buffered saline containing 4% formaldehyde. Presence of cellsurface receptors was determined by flow cytometry (Duke University Flow Cytometry Facility).
RESULTS

␤-Arrestin2
Selectively Enhances JNK3 but Not MKK4 Phosphorylation Stimulated by ASK1-We have previously shown that ␤-arrestin2 interacts with the MAP kinase JNK3 and the MAP3 kinase ASK1 to strongly enhance JNK3 phosphorylation (pThr-Pro-pTyr) stimulated by ASK1 (20) . Transfection of increasing amounts of ASK1 alone results in an increase of JNK3 phosphorylation up to ϳ3-fold (Fig. 1A) . In the presence of ␤-arrestin1, ASK1-stimulated phosphorylation of JNK3 is enhanced moderately up to ϳ8-fold. However, in the presence of ␤-arrestin2, phosphorylation of JNK3 is strongly enhanced up to ϳ35-fold. Whole cell extracts were analyzed for ASK1, JNK3, and ␤-arrestin levels to ensure equivalent expression of the ␤-Arrestin2 Stimulation of JNK3 Signalingtransfected proteins (Fig. 1A , lower panels and data not shown).
To gain additional insight into the mechanism by which ␤-arrestin2 enhances signaling to the MAP kinase JNK3, we analyzed the effect of the ␤-arrestins on ASK1-stimulated phosphorylation of the MAP2 kinase MKK4. Transfection of increasing amounts of ASK1 results in robust phosphorylation of MKK4 that is unaffected by either ␤-arrestin1 or ␤-arrestin2 (Fig. 1B, upper panel) . Whole cell extracts were analyzed for ASK1, MKK4, and ␤-arrestin protein levels to ensure equal expression of the transfected proteins (Fig. 1B , lower panels and data not shown). Therefore, under our experimental conditions, overexpression of ASK1 alone is sufficient to promote signals leading to phosphorylation of MKK4. However, ␤-arrestin2 is required to promote signaling leading to phosphorylation of JNK3.
␤-Arrestin2 Enhances JNK3 Phosphorylation Stimulated by MKK4 - Fig. 1 suggests that a major function of ␤-arrestin2 as a scaffold protein in the JNK3 signaling cascade is to enhance signaling from MKK4 to JNK3. We therefore analyzed whether the ␤-arrestins could support strong JNK3 phosphorylation stimulated by MKK4 (Fig. 2, upper panel) . Similar to the effect of the ␤-arrestins on JNK3 phosphorylation stimulated by ASK1, ␤-arrestin2 strongly enhances JNK3 phosphorylation stimulated by increasing amounts of MKK4 (0.03-0.100 g of plasmid DNA). Although ␤-arrestin1 weakly enhances JNK3 phosphorylation stimulated by ASK1, there is no effect of ␤-arrestin1 on enhancement of JNK3 phosphorylation stimulated by MKK4. Whole cell extracts were analyzed by immunoblot for MKK4 levels to ensure equivalent levels of the stimulatory upstream kinase (Fig. 2, lower panel) . Recent data indicates that stimulation of JNK3 phosphorylation by anisomycin requires activation of MKK4, as cells deficient in MKK4 do not respond to acute stimulation with anisomycin (29) . Transfection of ␤-arrestin2, but not ␤-arrestin1, also specifically enhances JNK3 phosphorylation stimulated by acute treatment with anisomycin (data not shown). These results indicate that at least one function of ␤-arrestin2 is to specifically enhance signaling from MKK4 to JNK3.
The Carboxyl Terminus of ␤-Arrestin2 Contains the Major Binding Site for JNK3-Because ␤-arrestin2 is a very strong stimulator of JNK3 phosphorylation in comparison with ␤-arrestin1, we hypothesized that the generation of chimeric molecules of ␤-arrestin1 and ␤-arrestin2 would be useful to further understand the effect of ␤-arrestin2 on stimulation of JNK3 phosphorylation. The crystal structure of the closely related visual arrestin protein indicates that the ␤-arrestins would be predicted to be bipartite molecules with two distinct domains separated by a small linker comprised of amino acids 181-187. The ␤-arrestin1/2 chimera consists of amino acids 1-184 of ␤-arrestin1 and amino acids 186 -410 of ␤-arrestin2. The ␤-arrestin2/1 chimera consists of amino acids 1-185 of ␤-arrestin2 and amino acids 185-418 of ␤-arrestin1. The basic structures of the chimeras are shown in Fig. 3A , and the ␤-arrestin2 sequences are depicted in black, while ␤-arrestin1 sequences are depicted in white. FLAG-tagged expression plasmids for the ␤-arrestin chimeras, wild-type ␤-arrestin1, and wild-type ␤-arrestin2 were transfected into COS-7 cells with HA-tagged JNK3. The JNK3 was immunoprecipitated with anti-HA antibody and bound ␤-arrestins were analyzed by immunoblot using FLAG antibody (Fig. 3B, upper panel) . The weak signal in the control lane represents nonspecific binding of ␤-arrestin2 to the antibody used in the immunoprecipitations. In agreement with our earlier findings, ␤-arrestin2 interacts strongly with JNK3, although ␤-arrestin1 exhibits weak binding to JNK3. The ␤-arrestin1/2 chimera, but not the ␤-arrestin2/1 chimera interacted strongly with JNK3 indicating that the carboxyl terminus of ␤-arrestin2 contains the major determinants for JNK3 interaction. Analysis of the ␤-arrestin expression in whole cell extracts confirmed that the wild-type and chimeric proteins were expressed equivalently (Fig. 3B, lower panel) .
The Carboxyl Terminus of ␤-Arrestin2 Is Essential for Strong Enhancement of ASK1-stimulated JNK3 PhosphorylationOverexpression of ASK1 results in a low level of JNK3 phosphorylation that is strongly enhanced by ␤-arrestin2 but not by ␤-arrestin1 (Fig. 1A, top panel) . Because the ␤-arrestin1/2 chimera retains strong JNK3 binding equivalent to ␤-arrestin2, we hypothesized that the ␤-arrestin1/2 chimera would enhance JNK3 phosphorylation similarly to wild-type ␤-arrestin2. 
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COS-7 cells expressing ␤-arrestin1, ␤-arrestin1/2, ␤-arrestin2/1, or ␤-arrestin2 along with JNK3 and increasing amounts of ASK1 (0.1-1.0 g of plasmid DNA) were analyzed for phospho-JNK3 (Fig. 4A, top panel) . As expected ␤-arrestin1 exhibited weak enhancement of JNK3 phosphorylation, although ␤-arrestin2 strongly enhanced JNK3 phosphorylation. The ␤-arrestin1/2 chimera that binds strongly to JNK3 also is a strong inducer of JNK3 phosphorylation, similar to the levels induced by ␤-arrestin2. In contrast, the ␤-arrestin2/1 chimera is a weak inducer of JNK3 phosphorylation similar to ␤-arrestin1. Whole cell extracts were analyzed for ASK1 expression to ensure equal expression of the stimulatory upstream kinase (Fig. 4A, lower panel) . The effect of the ␤-arrestins on JNK3 phosphorylation is shown in graphic form as analyzed by quantitation of phospho-JNK3 on immunoblots (Fig. 4B) . To more precisely map the region required for enhanced JNK3 phosphorylation, additional chimeras were constructed that switch amino acid residues carboxyl-terminal to amino acids 333/335 of the ␤-arrestins. A chimera that contains the first 335 amino acids of ␤-arrestin2 and the last 85 amino acids of ␤-arrestin1 strongly enhances ASK1-stimulated JNK3 phosphorylation although the reverse chimera weakly enhances JNK3 phosphorylation (data not shown). These data indicate that amino acids 186 -335 of ␤-arrestin2 contain the determinants for strong enhancement of JNK3 phosphorylation.
Identification of Key Residues in the Carboxyl Terminus of ␤-Arrestin2
Essential for JNK3 Interaction-␤-arrestin1 and ␤-arrestin2 differ significantly in their ability to stimulate JNK3 phosphorylation. However, ␤-arrestin1 and ␤-arrestin2 are 81% identical in the region that contains determinants for low or high level induction of JNK3 phosphorylation (amino acids 186 -335) (Fig. 5A ). One striking difference is amino acids 196 -198 of ␤-arrestin2 (195-196 of ␤-arrestin1). Interestingly, these amino acids are also very similar to the conserved docking motif present in many MAP kinase-binding proteins. This region encodes Lys-Pro (KP) in ␤-arrestin1 and Arg-Arg-Ser (RRS) in ␤-arrestin2. We hypothesized that these amino acids could be responsible for the dramatic difference in the function of these two proteins. To test this hypothesis we constructed mutants of each protein that contain the corresponding residues from the other ␤-arrestin isoform. ␤-Arrestin2(KP) is therefore a full-length ␤-arrestin2 molecule with the RRS residues replaced with KP. ␤-Arrestin1(RRS) is a full-length ␤-arrestin1 molecule with the KP residues replaced with RRS.
To test the effect of mutation of these amino acids on JNK3 interaction, we transfected HA-JNK3 along with FLAG-tagged ␤-arrestin1, ␤-arrestin(RRS), ␤-arrestin2(KP), or ␤-arrestin2 into COS-7 cells. JNK3 was immunoprecipitated with anti-HA antibodies, associated ␤-arrestin proteins were detected by immunoblot, and the relative strengths of interaction were determined by quantitation of band intensities in comparison with ␤-arrestin2 (Fig. 5B, upper panel) . The weak signal in the control lane represents nonspecific binding of ␤-arrestin 2 to the antibody used in the immunoprecipitations. As expected, ␤-arrestin2 interacted strongly with JNK3. However, introduction of the KP residues into ␤-arrestin2 significantly decreased the strength of the interaction to ϳ20% of the binding observed with wild-type ␤-arrestin2. Similar to our earlier findings, the relative strength of ␤-arrestin1 interaction with JNK3 is ϳ10% 
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of the binding observed with wild-type ␤-arrestin2. Interestingly, introduction of the RRS amino acids into ␤-arrestin1 increased the strength of the interaction with JNK3 to ϳ40% of the binding observed with wild-type ␤-arrestin2. Thus, whereas ␤-arrestin2(KP) is a severe loss-of-function mutant for JNK3 binding, ␤-arrestin1(RRS) appears to be a partial gainof-function mutation. Whole cell extracts were blotted for ␤-arrestin expression to ensure that introduction of point mutations did not dramatically affect protein expression (Fig. 5B,  lower panel) .
We previously noted that ␤-arrestin2 interacts with both JNK3 and ASK1 to stimulate JNK3 phosphorylation (20) . Because the RRS residues (present in wild-type ␤-arrestin2) and the KP residues (present in wild-type ␤-arrestin1) appear to have a dramatic effect on interaction with JNK3, we tested the ability of the mutated ␤-arrestins to interact with ASK1. HA-ASK1 and each of the ␤-arrestins were transfected into COS-7 cells. ASK1 was immunoprecipitated with anti-HA antibodies and bound ␤-arrestins were analyzed by immunoblot (Fig. 5C,  upper panel) . In contrast to JNK3, ASK1 appears to interact equivalently with the wild-type ␤-arrestins and corresponding point mutants. It appears that both ␤-arrestin1 and 2 are capable of interaction with ASK1, and that the presence of the RRS motif in ␤-arrestin2 then supports the assembly of JNK3 into the ␤-arrestin2 complex.
The RRS/KP Motif in the ␤-Arrestins Controls High Level JNK3 Phosphorylation Stimulated by ASK1-Replacement of the RRS motif with KP in ␤-arrestin2 severely reduced JNK3 interaction, although the corresponding replacement of KP with RRS in ␤-arrestin1 increased the interaction with JNK3. These results suggest that these ␤-arrestin point mutants would have altered capacity to enhance ASK1-stimulated JNK3 phosphorylation. To test this hypothesis, COS-7 cells expressing ␤-arrestin1, ␤-arrestin1(RRS), ␤-arrestin2(KP), or ␤-arrestin2 along with JNK3 and increasing amounts of ASK1 (0.1-1.0 g of plasmid DNA) were analyzed for phospho-JNK3 (Fig. 6A, upper panel) . Whereas ␤-arrestin1 weakly enhances ASK1-stimulated JNK3 phosphorylation, the ␤-arrestin1(RRS) mutant is a partial gain-of-function mutation similar to its increased ability to interact with JNK3. Additionally, whereas wild-type ␤-arrestin2 strongly enhances JNK3 phosphorylation, the ␤-arrestin2(KP) mutant is largely defective similar to ␤-arrestin1. Fig. 6B shows the results in graphic from. Whereas the ␤-arrestin1(RRS) mutant approaches ϳ75% of the activity of wild-type ␤-arrestin2 at the highest ASK1 concentration tested, the partial gain-of-function phenotype is par- ␤-Arrestin2 Stimulation of JNK3 Signalingticularly obvious at low ASK1 concentrations. The ␤-arrestin2(KP) mutant appears to be comparable in activity to wild-type ␤-arrestin1 at all concentrations of ASK1 examined. Interestingly, the ␤-arrestin point mutations (RRS and KP) highlight the strong correlation between the ability of the ␤-arrestins to bind JNK3 and to enhance ASK1-stimulated JNK3 phosphorylation. The data suggest that the proximal region of the carboxyl-terminal domain in the ␤-arrestins (which is homologous to the conserved domains in MAP kinase-binding proteins) is important for the function of ␤-arrestin as a MAPK scaffold because of its ability to strongly interact with JNK3. The presence of the RRS motif appears to enable ␤-arrestin2 to direct efficient assembly and activation of an ASK1/JNK3 complex.
The RRS/KP Motif in the ␤-Arrestins Does Not Affect Receptor Internalization-The striking difference between the ␤-arrestins with respect to their function as scaffolds in the JNK3 pathway may represent a function of the ␤-arrestins that is distinct from their role in receptor internalization. To address this possibility, the wild-type ␤-arrestins and the RRS/KP mutants were tested for their ability to support isoproterenol (iso)-stimulated internalization of the ␤2-adrenergic receptor. Each of the ␤-arrestins was transfected into COS-7 cells with the ␤2-adrenergic receptor and the presence of cell-surface receptors was analyzed by fluorescence-activated cell sorting (Fig. 7) . In agreement with published results, both ␤-arrestin1 and ␤-arrestin2 increased iso-induced internalization of the ␤2-adrenergic receptor (30, 31) . ␤-Arrestin2 was typically slightly stronger than ␤-arrestin1 (31% versus 23% internalization). Moreover, ␤-arrestin1(RRS) was identical to wild-type ␤-arrestin1, while ␤-arrestin2(KP) was identical to wild-type ␤-arrestin2. These results are in contrast to the dramatic effect of these mutations on ASK1-stimulated JNK3 phosphorylation and indicate that the structural determinants for JNK3 stimulation are distinct from those involved in receptor internalization. DISCUSSION We present evidence in this study that specific residues in the carboxyl terminus of ␤-arrestin2 facilitate the assembly of a complex that contains JNK3. ␤-Arrestin2 appears to act as a scaffold protein to enhance signaling through the MAP kinase cascade resulting in the robust phosphorylation of JNK3. Although the ␤-arrestins appear to be highly conserved in both sequence and function, ␤-arrestin1 only weakly enhances JNK3 phosphorylation. Differences do exist in the relative affinity of the ␤-arrestins for different GPCRs, and the ability of ␤-arrestin2 to direct high level phosphorylation of JNK3 may enable GPCRs with a higher affinity for ␤-arrestin2 (in comparison with ␤-arrestin1) to induce strong activation of JNK3 signaling (32) . Alternatively, the different ␤-arrestins may function as scaffolds for different MAP kinases. In the case of the ERKs, ␤-arrestin1 and ␤-arrestin2 both can participate in the formation of multicomponent complexes containing at least ERK and the upstream kinases MEK and Raf (18, 19) .
Arrestin proteins appear to play widespread roles in the formation of multicomponent complexes involving MAP kinase signaling pathways. In addition to the mammalian examples involving ERK and JNK signaling pathways, recent reports suggest that similar complexes form with arrestin proteins in Drosophila (33, 34) . In the Drosophila compound eye, lightinduced conversion of rhodopsin to metarhodopsin can lead to the formation of stable rhodospin/arrestin2 complexes that induce apoptosis. Because the induction of apoptosis is often associated with activation of JNK signaling cascades (4), it is tempting to speculate that rhodopsin/arrestin complexes contain MAPK signaling proteins similar to those we have observed with the ␤-arrestins.
The ␤-arrestins function in a manner similar to a large 
family of scaffold proteins that all enhance signaling through multikinase signaling pathways. The first of these proteins to be discovered was the Ste5 protein in yeast (22, 35, 36) . Ste5 is an essential protein that enhances pheromone signaling in Saccharomyces cerevisiae. Recently, several mammalian proteins have been discovered that are functionally (not structurally) related to Ste5. MEK-interacting protein 1 (MP1) is involved in stimulation of ERK signaling and JNK-interacting proteins (JIP, JSAP1) serve very analogous roles directing phosphorylation of the JNK proteins (23, 24, (37) (38) (39) . Other mammalian scaffold proteins have been discovered that function in MAP kinase-related pathways such as the IKAP protein in the NF-B pathway (40, 41) . Thus, it appears that these proteins are essential for directing the proper assembly of a group of closely related pathways. These proteins not only direct the assembly of the kinase cascades, but also prevent inappropriate cross-talk between the kinases of related cascades. The detailed mechanisms by which each of these scaffolds function are still being elucidated, but it appears that there is not a single set of rules that all scaffolds follow. The mechanism by which ␤-arrestin2 directs phosphorylation of JNK3 appears to be unique, although similarities can clearly be seen with the other scaffold proteins. Ste5, unlike the mammalian MP1 and JIP proteins, is regulated by activation of a GPCR (Ste2) in yeast (42) . This regulation of Ste5 is similar to mammalian GPCR regulation of ␤-arrestin proteins. We have previously shown that agonist stimulation of the AT1aR regulates both the cellular distribution and activation of JNK3 in a ␤-arrestin2-dependent manner (20) . In contrast to Ste5 and the JIP proteins, ␤-arrestin2 directly interacts with only two of the kinases in the JNK3 pathway (ASK1 and JNK3). MKK4 is also recruited to the ␤-arrestin2 complex, however, the interaction appears to be indirect, occurring through interaction with either JNK3 or ASK1 (20) . Fig. 8 depicts a model that is consistent with our data. A major effect of ␤-arrestin2 is the enhancement of JNK3 phosphorylation mediated by MKK4. ASK1 is capable of phosphorylating MKK4, but this does not result in JNK3 phosphorylation unless ␤-arrestin2 is expressed. Thus, although ASK1 and MKK4 get recruited to a ␤-arrestin2 scaffold, the effect of ␤-arrestin2 appears to involve an interaction with JNK3 that increases the efficiency with which JNK3 is phosphorylated by its upstream kinase MKK4. This specific enhancement of communication between the MAP2 kinase (MKK4) and the MAP kinase (JNK3) by ␤-arrestin2 is similar to the effects of the MP1 scaffold for ERK. MP1 specifically interacts with the MAP2 kinase (MEK1) and the MAP kinase (ERK1) and enhances the signaling between these two kinases (37) . Moreover, although the scaffold proteins are similar in that they physically recruit multiple members of their respective MAP kinase cascades, the specific mechanism by which each scaffold functions may be unique.
It appears that the RRS/KP residues in the ␤-arrestins are involved in the interaction with JNK3 and stimulation of JNK3 phosphorylation. Replacement of the RRS residues in ␤-arrestin2 with KP residues greatly decreased the interaction with JNK3, while not affecting the interaction with ASK1. Similarly, replacement of the KP residues in ␤-arrestin1 with RRS residues increased interaction with JNK3, while not affecting the interaction with ASK1. The level of JNK3 binding by these ␤-arrestin mutants was directly correlated with the ability to enhance JNK3 phosphorylation indicating that these residues are directly involved in the scaffold function of the ␤-arrestins with respect to the JNK3 MAP kinase pathway.
The structural basis for the interaction of proteins with MAP kinases has drawn considerable attention in recent years. Several reports indicate that a conserved docking site is present in a large number of MAPK-binding proteins such as MAP2Ks and MAP kinase phosphatases (43) (44) (45) . The consensus sequence for this docking site is (K/R)(K/R)X 1-6 (I/L)X(I/L). Although somewhat loosely defined, many of these MAP kinasebinding proteins have this motif, which is comprised of a cluster of two basic residues (Lys or Arg) separated by a spacer of 1 to 6 residues and a hydophobic-X-hydophobic sequence (Ile or Leu). The RRS region of ␤-arrestin2 matches almost identically to this docking site (RRSLHL) while ␤-arrestin1 contains a similar region (KPLHL). It appears that the more closely matching docking site in ␤-arrestin2 is capable of mediating high level JNK3 binding and enhancement of phosphorylation whereas the less related sequence in ␤-arrestin1 supports only low level JNK3 binding and enhancement of JNK3 phosphorylation. Mutational analysis of the docking site in MEK1 with respect to interaction with ERK2 and JNK1 indicates that mutation of either the basic residues or the hydophobic residues severely compromises MEK1 interaction with both ERK2 and JNK1 (45) . This suggests that both halves of the consensus docking site play important roles in the interaction with MAP kinases. Our data suggest that the basic residues provide some docking site specificity with respect to JNK3 interaction. Whereas both ␤-arrestin1 and ␤-arrestin2 contain good matches with the hydophobic portion of the docking site, the basic residues in ␤-arrestin2 (RRS versus KP in ␤-arrestin1) play an important role, as the strength of JNK3 binding and enhancement of JNK3 phosphorylation is clearly affected by exchanging these residues. Interestingly, both ␤-arrestin1 and ␤-arrestin2 interact with and affect ERK activity (18 -19) . This suggests that the docking sites in both ␤-arrestin1 and ␤-arrestin2 have comparable affinities for the ERKs. More detailed analysis of the interactions of the ␤-arrestins with other MAP kinases will likely provide a better understanding of specific docking site residues required for interaction with MAP kinases.
The role of receptor internalization in the formation of ␤-arrestin-associated MAP kinase scaffolds is still unknown. Expression of the ␤-arrestins can clearly enhance signaling though JNK and ERK pathways stimulated by overexpression of MAP3 kinases. However agonist stimulation of GPCRs ap- pears to play an important role in directing the subcellular location of active ␤-arrestin/MAP kinase complexes (19, 20) . It is likely that in the absence of MAP3 kinase overexpression, receptor stimulation is required for the activation of upstream kinases such as ASK1 and Raf. The recruitment of ␤-arrestin to activated receptors then allows the phosphorylation signal to proceed to the MAPK and the entire complex is internalized. Our data with the RRS docking site mutants indicate that the ability of ␤-arrestin2 to assemble the JNK3 complex is separable from its ability to drive receptor internalization. Whereas introduction of the KP residues into ␤-arrestin2 (␤-arrestin2 (KP)) severely compromises its ability to enhance JNK3 phosphorylation, there is no effect on the ability of ␤-arrestin2 to promote receptor internalization. The same is true for ␤-arrestin1 whether the wild-type KP residues are present or the mutant RRS residues are present. These data indicate that whereas the scaffold and internalization functions of the ␤-arrestins may occur simultaneously, the specific mechanism by which ␤-arrestins mediate these functions is different.
Taken together, these findings indicate that the ␤-arrestins have a specific function in mediating signal transmission through the JNK3 MAP kinase. The data indicate that specific residues in the carboxyl terminus mediate the interaction of ␤-arrestin2 with JNK3 and enhance the ability of the MAP2 kinase MKK4 to phosphorylate JNK3. Moreover, these residues have considerable homology with the conserved docking site in other MAP kinase-binding proteins suggesting that the ␤-arrestins may use a similar mechanism for binding JNK3. Future studies on ␤-arrestin2 and the function of this conserved docking site should provide considerable new insights into not only details of ␤-arrestin and GPCR signaling to MAP kinases, but also into how the scaffolds function to enhance and provide specificity in MAP kinase signaling.
